Follow the Theriva Biologics, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €10.1m. The latest transaction was reported on 8 June 2023 (Acquisition). Among the most active insiders: SHALLCROSS STEVEN A. Every trade is openly available.
7
Insider Decl.
n/a
Thresholds
€148,488
7 ops.
Buy Volume
n/a
n/a
Sell Volume
34Σ signal
Buys €148,488n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
100,000 shares@ US$0.43727.7% of flowCommon StockSEC:0001104659-23-000023:0
Canonical exit: 29 Mar 2023 (T+90)
7 of 7 declarations
Acerca de Theriva Biologics, Inc.
Theriva Biologics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias innovadoras para enfermedades graves. Cotiza en el mercado XNAS.